Bruna Albino Rafael Matos Andrade
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Bruna Albino Rafael Matos Andrade has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Antonio Carlos Bianco
Section of Adult and Pediatric Endocrinology and Metabolism, University of Chicago
1 shared publication - Daniele Carvalhal de Almeida Beltrão
Department of Internal Medicine, Centro Universitário de João Pessoa (UNIPÊ) , João Pessoa, Paraíba 58053-000
1 shared publication - Danielle Albino Rafael Matos
Department of Internal Medicine, Lauro Wanderley University Hospital, Federal University of Paraíba , João Pessoa, Paraíba 58059-900
1 shared publication - Fabyan Esberard de Lima Beltrão
Department of Internal Medicine, University of Texas Medical Branch , Galveston, TX 77555
1 shared publication - Fabyo Napoleão de Lima Beltrão
Department of Internal Medicine, Faculty of Medical Sciences , João Pessoa 58010-630
1 shared publication - George Golovko
Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, USA
1 shared publication
Latest Publications
- 20 June 2025
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 111 (2) , 561-571
Treatment of Hypothyroidism That Contains Liothyronine is Associated With Reduced Risk of Dementia and Mortality
Introduction: Standard levothyroxine (LT4) therapy may not fully address all risks associated with hypothyroidism—especially cognitive decline, dementia, and mortality—even when TSH levels are normalized. Observational studies link hypothyroidism to higher dementia rates; the role of LT4 plus T3 therapies remains uncertain. Methods: This retrospective cohort study analyzed TriNetX data, comparing 1.26 million patients with hypothyroidism (on LT4, LT4 + T3, or desiccated thyroid extract) to 3.32 million controls. Outcomes included dementia, atrial fibrillation, and mortality over 20 years of follow-up. Propensity score matching was used to balance covariates for age, sex, and comorbidities. Adjusted hazard ratios were obtained via Cox proportional hazard modeling. A parallel systematic review and meta-analysis of 12 studies evaluated dementia risk in hypothyroidism. Results: Patients with hypothyroidism showed a ∼1.4-fold higher risk of dementia and a >2.0-fold increase in mortality—even with normal TSH—and these risks were most pronounced when TSH levels were off-target. A parallel meta-analysis indicated a 1.4-fold heightened dementia risk. In cohorts formed by propensity score matching comparing LT4 monotherapy vs combination therapy, relative risk analysis indicated 27% and 31% lower dementia and mortality risks, respectively, with combination therapy. The adjusted Cox model (hazard ratio) showed 16% and 25% reductions in these outcomes for combination therapy patients. Conclusion: Despite standard LT4 therapy, hypothyroidism remains associated with heightened risks of dementia and mortality. Adding T3 may more effectively mitigate these risks than LT4 alone, but further studies are needed to confirm the cognitive and survival benefits of T3-containing regimens.
- 20 June 2025
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 111 (2) , 561-571
Treatment of Hypothyroidism That Contains Liothyronine is Associated With Reduced Risk of Dementia and Mortality
Introduction: Standard levothyroxine (LT4) therapy may not fully address all risks associated with hypothyroidism—especially cognitive decline, dementia, and mortality—even when TSH levels are normalized. Observational studies link hypothyroidism to higher dementia rates; the role of LT4 plus T3 therapies remains uncertain. Methods: This retrospective cohort study analyzed TriNetX data, comparing 1.26 million patients with hypothyroidism (on LT4, LT4 + T3, or desiccated thyroid extract) to 3.32 million controls. Outcomes included dementia, atrial fibrillation, and mortality over 20 years of follow-up. Propensity score matching was used to balance covariates for age, sex, and comorbidities. Adjusted hazard ratios were obtained via Cox proportional hazard modeling. A parallel systematic review and meta-analysis of 12 studies evaluated dementia risk in hypothyroidism. Results: Patients with hypothyroidism showed a ∼1.4-fold higher risk of dementia and a >2.0-fold increase in mortality—even with normal TSH—and these risks were most pronounced when TSH levels were off-target. A parallel meta-analysis indicated a 1.4-fold heightened dementia risk. In cohorts formed by propensity score matching comparing LT4 monotherapy vs combination therapy, relative risk analysis indicated 27% and 31% lower dementia and mortality risks, respectively, with combination therapy. The adjusted Cox model (hazard ratio) showed 16% and 25% reductions in these outcomes for combination therapy patients. Conclusion: Despite standard LT4 therapy, hypothyroidism remains associated with heightened risks of dementia and mortality. Adding T3 may more effectively mitigate these risks than LT4 alone, but further studies are needed to confirm the cognitive and survival benefits of T3-containing regimens.